Find Paid Clinical Trials for Cancer in Canada

Paid Clinical Trials and Focus Groups by Category

All Categories ... by Medical Condition » ... Cancers » ... Canada

Oral Glutamine in the Prevention of Oxaliplatin-induced Neurotoxicity

Condition: Colorectal Neoplasms
Interventions: Drug: Glutamine; Drug: Calcium and Magnesium
Sponsor: Sanofi-Aventis
Recruiting - verified March 2010
Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer

Conditions: Advanced Gastric Cancer; Gastro-esophageal Junction Cancer
Interventions: Drug: AUY922; Drug: Docetaxel or Irinotecan
Sponsor: Novartis Pharmaceuticals
Not yet recruiting - verified March 2010
Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

Condition: Ovarian Cancer
Interventions: Drug: olaparib; Drug: paclitaxel; Drug: carboplatin
Sponsor: AstraZeneca
Recruiting - verified March 2010
A Study Evaluating the Clinical Benefit of Adding Custirsen to Docetaxel Retreatment/Prednisone as Second Line Therapy in Men With Castrate Resistant Prostate Cancer (CRPC)

Conditions: Castrate-Resistant Prostate Cancer; Hormone Refractory Prostate Cancer
Interventions: Drug: custirsen sodium; Drug: Isotonic, 0.9% sodium chloride
Sponsors: OncoGenex Technologies; Teva Pharmaceuticals USA
Not yet recruiting - verified March 2010
Living With Hope Program for Rural Women Caregivers

Condition: Advanced Cancer
Intervention: Behavioral: Living with Hope Program
Sponsor: University of Saskatchewan
Recruiting - verified March 2010
SB939 in Treating Patients With Recurrent or Metastatic Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: HDAC inhibitor SB939; Other: laboratory biomarker analysis
Sponsor: NCIC Clinical Trials Group
Recruiting - verified February 2010
Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Ovarian Cancer and Inoperable Malignant Bowel Obstruction

Conditions: Ovarian Cancer; Bowel Obstruction
Interventions: Drug: Cisplatin; Drug: Paclitaxel
Sponsor: University Health Network, Toronto
Recruiting - verified February 2010
Decision Making on Radioactive Iodine Treatment for Papillary Thyroid Cancer

Condition: Thyroid Cancer
Intervention: Other: Decision aid exposure
Sponsors: University Health Network, Toronto; Ontario Ministry of Health and Long Term Care; Canadian Institutes of Health Research (CIHR)
Recruiting - verified January 2010
Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)

Condition: Acute Myeloid Leukemia
Interventions: Drug: A: Azacitidine (Vidaza); Drug: B: Conventional Care Regimen
Sponsor: Celgene Corporation
Not yet recruiting - verified February 2010
Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy

Condition: Infantile Hemangioma
Interventions: Drug: Propranolol; Drug: Placebo
Sponsor: Pierre Fabre Dermatology
Recruiting - verified March 2010
Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)

Condition: Gastro-Intestinal Cancer
Interventions: Drug: 5-FU; Drug: Leucovorin; Drug: 5-FU; Drug: Irinotecan; Drug: Brivanib; Drug: Brivanib; Drug: Brivanib
Sponsor: Bristol-Myers Squibb
Recruiting - verified March 2010
Efficacy of Ultrasound Contrast Agent to Assess Renal Masses

Condition: Renal Cell Carcinoma
Intervention: Drug: Definity
Sponsors: University Health Network, Toronto; Lantheus Medical Imaging
Recruiting - verified February 2010
Comparison of Two Doses of Mannitol on Brain Relaxation During Supratentorial Craniotomy

Conditions: Brain Tumor; Intracranial Pressure
Interventions: Drug: Mannitol; Drug: Mannitol
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
Not yet recruiting - verified February 2010
Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: prednisone; Drug: vincristine sulfate; Drug: vinorelbine ditartrate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen

Condition: Leukemia
Intervention: Drug: AEG35156
Sponsor: Aegera Therapeutics
Recruiting - verified February 2010
Temsirolimus and Bevacizumab in Treating Patients With Locally Advanced, Recurrent, Metastatic, or Progressive Endometrial Cancer, Ovarian Epithelial Cancer, Liver Cancer, Islet Cell Cancer, or Carcinoid Tumor

Conditions: Endometrial Cancer; Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Liver Cancer; Lung Cancer; Ovarian Cancer
Interventions: Biological: bevacizumab; Drug: temsirolimus; Other: laboratory biomarker analysis
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study of RO5072759 With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Condition: Lymphocytic Leukemia, Chronic
Interventions: Drug: RO5072759; Drug: rituximab; Drug: chlorambucil
Sponsors: Hoffmann-La Roche; Genentech
Recruiting - verified February 2010
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma

Condition: Malignant Melanoma
Interventions: Drug: RO5185426; Drug: dacarbazine
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
PF-00299804 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Standard Therapy for Advanced or Metastatic Cancer

Condition: Lung Cancer
Interventions: Drug: PF-00299804; Genetic: gene expression analysis; Genetic: mutation analysis; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: quality-of-life assessment
Sponsor: NCIC Clinical Trials Group
Recruiting - verified March 2010
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

Conditions: Lymphoma; Lymphoproliferative Disorder
Interventions: Other: biologic sample preservation procedure; Other: informational intervention
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Comparing Three Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Metastatic Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel; Procedure: quality-of-life assessment
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Liver Cancer

Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: liver transplantation; Procedure: therapeutic conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Patients With HER2-Positive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: pertuzumab; Drug: trastuzumab [Herceptin]; Drug: trastuzumab [Herceptin]; Drug: docetaxel; Drug: docetaxel; Drug: FEC: 5-Fluorouracil/epirubicin/cyclophosphamide; Drug: carboplatin; Drug: trastuzumab
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy

Condition: Castration-Resistant Prostate Cancer
Interventions: Drug: MDV3100; Drug: Placebo
Sponsor: Medivation, Inc.
Recruiting - verified March 2010
Figitumumab Combined With Pegvisomant For Advanced Solid Tumors

Conditions: Colorectal Neoplasms; Lung Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Sarcoma
Interventions: Drug: figitumumab; Drug: pegvisomant
Sponsor: Pfizer
Recruiting - verified March 2010
START Rollover Study

Condition: Leukemia
Interventions: Drug: Dasatinib; Drug: Imatinib
Sponsor: Bristol-Myers Squibb
Active, not recruiting - verified January 2010
Efficacy and Safety of Donor Lymphocytes Depleted of Alloreactive T-cells (ATIR™) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor

Conditions: Myeloid Leukemia; Lymphoblastic Leukemia; Lymphoma; Multiple Myeloma; Myelodysplastic Syndrome; Myeloproliferative Disorders
Intervention: Biological: Donor lymphocyte preparation depleted of functional alloreactive T-cells
Sponsor: Kiadis Pharma
Recruiting - verified March 2010
Effect of Bilateral Scalp Local Anesthesia on Post-Operative Pain in Patients Undergoing Brain Surgery and General Anaesthesia

Condition: Supratentorial Brain Surgery
Intervention: Procedure: Bilateral Scalp Nerve Blocks
Sponsors: St. Michael's Hospital, Toronto; The Physicians' Services Incorporated Foundation
Recruiting - verified February 2010
Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors

Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: Placebo; Drug: CP-690,550; Drug: Placebo; Drug: CP-690,550
Sponsor: Pfizer
Recruiting - verified March 2010
Study of Blood Samples From Newborns With Down Syndrome

Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: RNA analysis; Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: microarray analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: flow cytometry; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study to Compare Subcutaneous Versus Intravenous Administration of Herceptin (Trastuzumab) in Women With HER2Positive Early Breast Cancer

Condition: Breast Cancer
Interventions: Drug: trastuzumab [Herceptin]; Drug: trastuzumab [Herceptin]; Drug: docetaxel; Drug: 5-fluorouracil; Drug: epirubicin; Drug: cyclophosphamide
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Biological: dactinomycin; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: vincristine sulfate; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
BIBW 2992 Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

Conditions: Carcinoma, Non-Small-Cell Lung; Adenocarcinoma
Interventions: Drug: BIBW 2992; Drug: BIBW 2992; Drug: Cisplatin; Drug: Cisplatin; Drug: Pemetrexed; Drug: Pemetrexed
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Cone Beam Computed Tomography (CT) (CBCT) With and Without a Customized Vacuum Immobilization Device (CVID)

Condition: Rectal Cancer
Interventions: Device: prone pillow and simple ankle fixation device; Device: Customized Vacuum Immobilization Device (CVID)
Sponsor: University Health Network, Toronto
Recruiting - verified February 2010
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects

Conditions: Human Papillomavirus (HPV) Type 16/18 Infections; Cervical Neoplasia
Intervention: Procedure: Gynaecological follow-up
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: PF-02341066
Sponsor: Pfizer
Recruiting - verified March 2010
An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: PF-02341066; Drug: Pemetrexed; Drug: Docetaxel
Sponsor: Pfizer
Recruiting - verified March 2010
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Conditions: Cancer; Cataract; Low Bone Mineral Density; Osteopenia; Osteoporosis; Prostate Cancer
Interventions: Biological: Denosumab; Biological: Placebo
Sponsor: Amgen
Recruiting - verified March 2010
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors

Condition: Brain and Central Nervous System Tumors
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma

Conditions: Chordoma; Desmoid Tumor; Sarcoma
Interventions: Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Trans-Rectal Ultrasound-Guided (TRUS) Adverse Events

Condition: Prostate Cancer
Intervention:
Sponsor: University Health Network, Toronto
Active, not recruiting - verified February 2010
Automating Breast Radiation Therapy (RT)

Condition: Breast Cancer
Intervention: Procedure: Cone Beam CT
Sponsor: University Health Network, Toronto
Recruiting - verified February 2010
A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer

Condition: Small Cell Lung Carcinoma
Interventions: Drug: BMS-833923; Drug: Carboplatin; Drug: Etoposide
Sponsors: Bristol-Myers Squibb; Exelixis
Recruiting - verified February 2010
Cone Beam Computed Tomography (CT) Bladder

Condition: Bladder Cancer
Intervention: Other: Using Cone beam CT in patients with Bladder Cancer
Sponsor: University Health Network, Toronto
Recruiting - verified February 2010
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors

Conditions: Colorectal Cancer; Head and Neck Cancer; Neoplasm Metastasis
Interventions: Drug: BMS-754807; Drug: cetuximab (Erbitux®)
Sponsor: Bristol-Myers Squibb
Recruiting - verified November 2009
Sentinel Node Biopsy Following NeoAdjuvant Chemotherapy in Biopsy Proven Node Positive Breast Cancer

Conditions: Breast Cancer; Invasive Breast Cancer
Intervention: Procedure: Sentinel Lymph Node Biopsy
Sponsors: Centre hospitalier de l'Université de Montréal (CHUM); Fondation du cancer du sein du Québec
Recruiting - verified May 2009
Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)

Condition: B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Interventions: Drug: Lenalidomide; Drug: Chlorambucil
Sponsor: Celgene Corporation
Recruiting - verified February 2010
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

Condition: Neuroblastoma
Interventions: Genetic: loss of heterozygosity analysis; Other: cytology specimen collection procedure; Procedure: biopsy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas

Conditions: Stomach Neoplasms; Esophageal Neoplasms
Interventions: Drug: BMS-833923; Drug: Cisplatin; Drug: Capecitabine
Sponsors: Bristol-Myers Squibb; Exelixis
Recruiting - verified December 2009
Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC

Condition: Hepatocellular Carcinoma
Interventions: Drug: Brivanib; Drug: Brivanib Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified November 2009
Study of Kidney Tumors in Young Patients

Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Genetic: loss of heterozygosity analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: immunohistochemistry staining method; Procedure: computed tomography; Procedure: magnetic resonance imaging
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

Conditions: Leukemia; Neoplasm of Uncertain Malignant Potential; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Other: cytology specimen collection procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma

Condition: Sarcoma
Interventions: Other: biologic sample preservation procedure; Other: medical chart review
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Tissue From Young Patients With Cancer

Condition: Cancer
Interventions: Genetic: DNA analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma

Condition: Sarcoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma

Condition: Carcinoma, Hepatocellular
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006); Drug: Sorafenib (Nexavar, BAY43-9006) + Erlotinib, Tarceva
Sponsors: Bayer; Onyx Pharmaceuticals; OSI Pharmaceuticals; Hoffmann-La Roche
Recruiting - verified March 2010
Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Biological Samples From Young Patients With Hodgkin's Lymphoma

Condition: Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Comparison of AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive Non Small Cell Lung Cancer (NSCLC) Patients

Condition: Non Small Cell Lung Cancer
Interventions: Drug: AZD6244; Drug: docetaxel; Drug: Placebo
Sponsor: AstraZeneca
Recruiting - verified March 2010
Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma

Conditions: Mesothelioma; Pleural Mesothelioma
Interventions: Drug: Pemetrexed; Drug: Cisplatin
Sponsors: University Health Network, Toronto; Eli Lilly and Company
Recruiting - verified March 2010
A Study of Ixabepilone as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: Ixabepilone; Drug: Doxorubicin; Drug: Paclitaxel
Sponsor: Bristol-Myers Squibb
Recruiting - verified March 2010
A Study of Neutropenia and Anemia Management in Subjects With Solid Tumors Receiving Myelotoxic Chemotherapy

Conditions: Breast Cancer; Non-small Cell Lung Cancer; Ovarian Cancer; Small Cell Lung Cancer
Intervention:
Sponsor: Amgen
Recruiting - verified March 2010
A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors

Conditions: Advanced Solid Cancers; Metastatic Cancer
Intervention: Drug: Cdc7-inhibitor
Sponsors: Bristol-Myers Squibb; Exelixis
Recruiting - verified October 2009
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab; Drug: temozolomide; Other: placebo
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study Evaluating the Effects of Neratinib in Women With Early Stage Breast Cancer

Condition: Breast Cancer
Interventions: Drug: neratinib; Other: placebo
Sponsor: Wyeth
Recruiting - verified March 2010
Study of Bendamustine Hydrochloride in Combination With Rituximab in the Treatment of Patients With Relapsed/Refractory Mantle Cell Lymphoma

Condition: Mantle Cell Lymphoma
Intervention: Drug: Bendamustine in combination with Rituximab
Sponsor: Cephalon
Recruiting - verified March 2010
Positron Emission Tomography(PET) in Lymphoma Assessment

Conditions: Hodgkin's Lymphoma; Non Hodgkin's Lymphoma
Intervention: Biological: PET Scan
Sponsor: University Health Network, Toronto
Recruiting - verified February 2010
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Conditions: Leukemia; Lymphoma
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: bortezomib; Drug: cyclophosphamide; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study of IMC-1121B in Combination With 5-FU/FA and Oxaliplatin Chemotherapies in Patients With Colorectal Cancer

Condition: Colorectal Carcinoma
Interventions: Biological: IMC-1121B; Drug: Oxaliplatin; Drug: Folinic acid; Drug: 5-FU; Drug: 5-FU
Sponsor: ImClone LLC
Active, not recruiting - verified February 2010
Study of Immunotherapy to Treat Advanced Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Repeat Dose Safety Study for Compound to Treat Hematologic Cancer

Condition: Hematologic Malignancies
Intervention: Drug: GSK21110183
Sponsor: Octagon Research Solutions, Inc.
Recruiting - verified February 2010
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia

Condition: Leukemia
Interventions: Drug: arsenic trioxide; Drug: cytarabine; Drug: idarubicin; Drug: mercaptopurine; Drug: methotrexate; Drug: mitoxantrone hydrochloride; Drug: tretinoin; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma

Condition: Malignant Melanoma
Interventions: Drug: ABI-007; Drug: Dacarbazine
Sponsors: Abraxis BioScience Inc.; University of Arizona
Recruiting - verified August 2009
A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer NSCLC.

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Nexavar (Sorafenib, BAY43-9006); Drug: Placebo
Sponsor: Bayer
Recruiting - verified March 2010
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole

Condition: Breast Cancer
Interventions: Drug: Everolimus, Exemestane; Drug: Placebo, Exemestane
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
A Phase 2 Open Label Trial of SGN-35 for Systemic Anaplastic Large Cell Lymphoma

Conditions: Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin
Intervention: Drug: SGN-35
Sponsor: Seattle Genetics, Inc.
Recruiting - verified February 2010
Anemia Treatment for Advanced NSCLC Patients Receiving Chemotherapy

Conditions: Non-small Cell Lung Cancer; Anemia; Cancer; Lung Cancer
Interventions: Drug: darbepoetin alfa 500 mcg Q3W; Drug: placebo
Sponsor: Amgen
Recruiting - verified March 2010
First Line Hepato Cellular Carcinoma (HCC)

Condition: Hepato Cellular Carcinoma (HCC)
Interventions: Drug: Brivanib; Drug: Placebo; Drug: Sorafenib; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified November 2009
Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).

Condition: Carcinoma, Hepatocellular
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006); Drug: Placebo
Sponsor: Bayer
Recruiting - verified March 2010
A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)

Condition: Non-small Cell Lung Cancer
Interventions: Drug: erlotinib HCl; Drug: MetMAb; Drug: placebo
Sponsor: Genentech
Recruiting - verified March 2010
A Trial of Patients With Metastatic Adenocarcinoma of the Pancreas

Condition: Metastatic Pancreatic Cancer
Interventions: Drug: ABI-007/Gemcitabine; Drug: Gemcitabine
Sponsor: Abraxis BioScience Inc.
Recruiting - verified December 2009
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse

Condition: Ovarian Cancer
Interventions: Drug: MORAb-003 (farletuzumab); Drug: MORAb-003 (farletuzumab); Drug: 0.9% Saline
Sponsor: Morphotek
Recruiting - verified October 2009
An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG 162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-Metastatic Prostate Cancer

Conditions: Cancer; Carcinoma; Castrate-Resistant Prostate Cancer; Prostate Cancer; Tumors
Intervention: Drug: Denosumab
Sponsor: Amgen
Recruiting - verified March 2010
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

Conditions: Adrenocortical Carcinoma; Kidney Cancer; Liver Cancer; Neuroblastoma; Retinoblastoma; Sarcoma
Interventions: Biological: cixutumumab; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment

Condition: Liver Cancer
Interventions: Drug: Brivanib; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified November 2009
Trial of BI 6727 Monotherapy and BI 6727 in Combination With Pemetrexed Compared to Pemetrexed Monotherapy in Advanced NSCLC

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: BI 6727; Drug: BI 6727; Drug: pemetrexed; Drug: pemetrexed
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Radiation Therapy and Cisplatin or Panitumumab in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Biological: panitumumab; Drug: cisplatin; Radiation: 3-dimensional conformal radiation therapy; Radiation: accelerated radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsor: NCIC Clinical Trials Group
Recruiting - verified March 2010
Health Education Materials With or Without a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer

Conditions: Anxiety Disorder; Cognitive/Functional Effects; Colorectal Cancer; Depression; Fatigue; Psychosocial Effects of Cancer and Its Treatment; Sleep Disorders
Interventions: Behavioral: exercise intervention; Other: counseling intervention; Other: educational intervention; Other: laboratory biomarker analysis; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: fatigue assessment and management; Procedure: quality-of-life assessment
Sponsor: NCIC Clinical Trials Group
Recruiting - verified March 2010
Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia

Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: OFC Infusion; Drug: FC infusion
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
A Phase I/II Study of IXO With Bevacizumab in Patients With Metastatic Colorectal Cancer

Condition: Metastatic Colorectal Cancer
Intervention: Drug: Irinotecan, Xeloda and Oxaliplatin (IXO) Regimen with Avastin (Bevacizumab)
Sponsors: Ottawa Hospital Research Institute; Hoffmann-La Roche; Pfizer; Sanofi-Aventis; Ottawa Regional Cancer Foundation
Recruiting - verified March 2010
A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients

Condition: Advanced or Metastatic ErbB2-overexpressing Breast Cancer
Intervention: Drug: Lapatinib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Pemetrexed; Drug: Pemetrexed; Drug: BIBF1120; Drug: Folic Acid; Drug: Folic Acid; Drug: BIBF1120 placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma

Conditions: Skin Cancer; Melanoma; Metastatic Melanoma
Interventions: Drug: temozolomide; Drug: ABT-888; Drug: Placebo
Sponsor: Abbott
Active, not recruiting - verified March 2010
Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib

Condition: Carcinoma, Hepatocellular
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
Sponsor: Bayer
Recruiting - verified March 2010
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US

Condition: Human Papillomavirus (HPV) Type 16/18 Infections and Cervical Neoplasia.
Intervention: Biological: GSK580299, GSK Biological's HPV vaccine
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: cediranib maleate; Drug: paclitaxel; Other: placebo
Sponsor: NCIC Clinical Trials Group
Recruiting - verified March 2010
Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers

Condition: Advanced Cancer
Interventions: Drug: Capecitabine; Drug: Doxorubicin; Drug: Ixabepilone; Drug: Docetaxel; Drug: Paclitaxel; Drug: Brivanib alaninate
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer

Condition: Ovarian Neoplasms
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006); Drug: Placebo
Sponsor: Bayer
Active, not recruiting - verified February 2010
Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid Tumors

Conditions: Advanced Solid Tumors; Metastatic Solid Tumors
Interventions: Drug: BMS-754807; Drug: Paclitaxel; Drug: Carboplatin
Sponsor: Bristol-Myers Squibb
Recruiting - verified February 2010
Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma

Condition: Multiple Myeloma
Intervention: Radiation: Total Marrow Irradiation
Sponsor: Ottawa Hospital Research Institute
Recruiting - verified March 2010
Rollover Protocol for Prior SU011248 Protocols

Condition: Solid Tumors
Intervention: Drug: Sunitinib
Sponsor: Pfizer
Recruiting - verified March 2010
A Study of Induction and Maintenance Treatment of Advanced Non-Squamous Non Small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Cisplatin; Drug: Placebo; Drug: Pemetrexed; Other: Best Supportive Care
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents

Conditions: Cancer; Solid Tumors
Interventions: Drug: Lapatinib in combination with an anti-cancer agent; Drug: Lapatinib; Drug: Lapatinib in combination with an anti-cancer agent as specified by parent protocol
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
PEAK: A Phase 2 Study of Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer Subjects With Wild-Type KRAS Tumors

Conditions: Colon Cancer; Colorectal Cancer; Rectal Cancer; Metastatic Colorectal Cancer
Interventions: Drug: Panitumumab; Drug: Bevacizumab; Drug: mFOLFOX6
Sponsor: Amgen
Recruiting - verified March 2010
Phase III, Open-label Study of Nilotinib Versus Imatinib in GIST Patients

Condition: Gastrointestinal Stromal Tumor (GIST)
Interventions: Drug: Nilotinib (AMN107); Drug: imatinib (STI571)
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: BMS-754807; Drug: trastuzumab (Herceptin®)
Sponsor: Bristol-Myers Squibb
Recruiting - verified March 2010
Short Neoadjuvant Hemithoracic IMRT for MPM

Condition: Malignant Pleural Mesothelioma
Intervention: Other: Pre-op RT +/- chemotherapy
Sponsor: University Health Network, Toronto
Recruiting - verified February 2010
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy

Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: RAD001; Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Phase II Study of TKI258 in Advanced Urothelial Carcinoma

Condition: Urothelial Cancer
Intervention: Drug: TKI258
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Efficacy and Safety of RAD001 in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)

Condition: Tuberous Sclerosis
Interventions: Drug: RAD001 (Everolimus); Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)

Conditions: Tuberous Sclerosis; Subependymal Giant Cell Astrocytoma
Interventions: Drug: Everolimus (RAD001); Other: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
A Study Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies

Condition: Cancer
Intervention: Drug: PF-04554878
Sponsor: Pfizer
Recruiting - verified March 2010
Study Evaluating Neratinib vs Lapatinib Plus Capecitabine for ErbB2 Positive Advanced Breast Cancer

Conditions: Advanced Breast Cancer; Breast Cancer
Interventions: Drug: Neratinib; Drug: Lapatinib plus Capecitabine
Sponsor: Wyeth
Recruiting - verified February 2010
Inositol in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia

Conditions: Lung Cancer; Precancerous Condition
Interventions: Dietary Supplement: inositol; Other: placebo
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified August 2009
Panitumumab Combination Study With AMG 102 or AMG 479 in Wild-type KRAS mCRC

Conditions: Colon Cancer; Colorectal Cancer; Gastrointestinal Cancer; Metastatic Colorectal Cancer; Rectal Cancer
Interventions: Drug: Panitumumab + AMG 102; Drug: Panitumumab + AMG 479; Drug: AMG 479; Drug: AMG 102; Drug: Panitumumab
Sponsor: Amgen
Recruiting - verified March 2010
A Feasibility Trial of Avastin (Bevacizumab) in Combination With Concomitant Chemoradiation (Cisplatin and Vinorelbine) in Patients With Locally Advanced Non-Squamous Non-Small Cell Lung Cancer.

Condition: Non-small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: cisplatin; Drug: vinorelbine
Sponsor: Hoffmann-La Roche
Active, not recruiting - verified February 2010
Neuropsychological and Behavioral Testing in Young Patients With Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor (PNET)

Conditions: Brain and Central Nervous System Tumors; Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Therapy-related Toxicity
Interventions: Other: questionnaire administration; Procedure: cognitive assessment; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Multicenter Clinical Study of the Sonablate®500 for the Treatment of Locally Recurrent Prostate Cancer With HIFU

Condition: Recurrent Prostate Cancer
Intervention: Device: High Intensity Focused Ultrasound
Sponsor: USHIFU, LLC
Recruiting - verified March 2010
Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer

Condition: Head and Neck Neoplasms
Intervention: Drug: PF-00299804
Sponsor: Pfizer
Recruiting - verified February 2010
AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer

Conditions: Cancer; Castrate-Resistant Prostate Cancer; Mestastatic Prostate Cancer; Prostate Cancer
Interventions: Drug: AMG 102; Drug: AMG 102
Sponsor: Amgen
Active, not recruiting - verified March 2010
Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: ridaforolimus; Genetic: gene expression analysis; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsor: NCIC Clinical Trials Group
Recruiting - verified January 2009
A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen

Condition: Non-small Cell Lung Cancer
Interventions: Drug: Erlotinib; Drug: PF-00299804
Sponsor: Pfizer
Recruiting - verified March 2010
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).

Condition: Non-small Cell Lung Cancer
Interventions: Drug: RG1507; Drug: Placebo; Drug: RG1507; Drug: Placebo; Drug: erlotinib [Tarceva]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Assessment of Efficacy of AZD2281 in Platinum Sensitive Serous Ovarian Cancer

Condition: Ovarian Cancer
Interventions: Drug: AZD2281; Drug: matching placebo
Sponsor: AstraZeneca
Active, not recruiting - verified March 2010
Prostate Active Surveillance Study

Condition: Prostatic Neoplasms
Intervention:
Sponsors: University of Washington; Canary Foundation; Early Detection Research Network
Recruiting - verified February 2010
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer

Condition: Prostatic Neoplasms
Interventions: Drug: placebo + docetaxel/prednisone; Drug: dasatinib + docetaxel/prednisone
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC

Condition: Non Small Cell Lung Cancer
Interventions: Drug: BMS-690514; Drug: Erlotinib
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Drug: ASA404 in combination with docetaxel; Drug: Placebo in combination with docetaxel
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma

Condition: Sarcoma
Interventions: Drug: cisplatin; Drug: dexrazoxane hydrochloride; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: leucovorin calcium; Drug: methotrexate; Drug: zoledronic acid; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716AM1)

Conditions: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung
Interventions: Drug: SCH 727965; Drug: Capecitabine; Drug: Erlotinib
Sponsor: Schering-Plough
Recruiting - verified March 2010
An Efficacy Study of MORAb-009 in Subjects With Pleural Mesothelioma

Condition: Malignant Pleural Mesothelioma
Intervention: Drug: MORAb-009 by IV on Days 1 and 8 every 21 days for 6 cycles.
Sponsor: Morphotek
Recruiting - verified March 2010
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Stage IIA, Stage IIIA, or Stage IIIB Rectal Cancer

Condition: Colorectal Cancer
Interventions: Procedure: therapeutic conventional surgery; Procedure: therapeutic laparoscopic surgery
Sponsors: American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified March 2010
BIBW 2992 With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma

Condition: Glioma
Interventions: Drug: TMZ; Drug: BIBW 2992 plus TMZ; Drug: BIBW 2992
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, or Osteosarcoma

Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Liver Cancer; Neuroblastoma; Ototoxicity; Ovarian Cancer; Sarcoma
Interventions: Drug: sodium thiosulfate; Procedure: examination
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer

Conditions: Esophagogastric Junction Adenocarcinoma; Gastric Cancer; Esophageal Cancer
Interventions: Drug: Capecitabine; Drug: Epirubicin; Drug: AMG 102; Drug: Cisplatin
Sponsor: Amgen
Recruiting - verified March 2010
Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma

Condition: Locally Advanced and/or Metastatic Renal Cell Carcinoma
Interventions: Drug: Sunitinib; Drug: Pazopanib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Chemotherapy and Radiation Therapy With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Drug: cisplatin; Drug: vandetanib; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dasatinib; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: ifosfamide; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: methylprednisolone; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma

Condition: Mantle Cell Lymphoma
Interventions: Drug: Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone; Drug: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone
Sponsors: Millennium Pharmaceuticals, Inc.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
Effect of Proactive Management of Side Effects on Treatment Compliance in Malignant Melanoma Patients on High-dose Intron A Therapy (Study P04600)

Condition: Melanoma
Intervention: Biological: Intron A (interferon alfa-2b; SCH 30500)
Sponsor: Schering-Plough
Recruiting - verified March 2010
Efficacy Study of XL184 in Adults With Medullary Thyroid Cancer

Condition: Thyroid Cancer
Interventions: Drug: XL184; Drug: Placebo
Sponsor: Exelixis
Recruiting - verified March 2010
Phase III Study of Docetaxel + IMC-1121B or Placebo in Breast Cancer

Condition: Breast Cancer
Intervention: Biological: IMCL-1121B
Sponsor: ImClone LLC
Recruiting - verified March 2010
A Phase III Study of Alpharadin (Radium-223)in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases

Conditions: Hormone Refractory Prostate Cancer; Bone Metastases
Interventions: Drug: Alpharadin (Radium-223); Drug: Placebo
Sponsor: Algeta ASA
Recruiting - verified March 2009
A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.

Condition: Non-small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: bevacizumab [Avastin]; Drug: Carboplatin-based chemotherapy
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer

Condition: Carcinoma, Hepatocellular
Interventions: Drug: sunitinib malate; Drug: sorafenib
Sponsor: Pfizer
Recruiting - verified March 2010
Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)

Condition: Carcinoma, Hepatocellular
Interventions: Drug: Nexavar (Sorafenib, BAY43-9006); Drug: Placebo
Sponsor: Bayer
Recruiting - verified March 2010
Bone Mineral Density in Postmenopausal Women at Increased Risk of Developing Breast Cancer And Who Are Receiving Exemestane on Clinical Trial CAN-NCIC-MAP3

Conditions: Breast Cancer; Osteoporosis
Interventions: Drug: exemestane; Other: biologic sample preservation procedure; Other: physiologic testing; Procedure: dual x-ray absorptometry
Sponsor: NCIC Clinical Trials Group
Recruiting - verified June 2009
Trial Assessing Zactima Against Placebo in Prostate Cancer Subjects Undergoing Intermittent Androgen Deprivation Hormonal Therapy

Condition: Prostate Cancer
Interventions: Drug: vandetanib; Drug: Placebo
Sponsors: AstraZeneca; Canadian Urology Research Consortium
Terminated - verified February 2010
Chemotherapy and Radiation in Treating Patients With Stage 3 Non-Small Cell Lung Cancer

Condition: Non Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Cisplatin; Drug: Etoposide; Drug: Cisplatin; Drug: Vinorelbine; Drug: Paclitaxel; Drug: Carboplatin; Radiation: Thoracic Radiation Therapy (TRT); Radiation: Thoracic Radiation Therapy (TRT)
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Genetic Mutations and Environmental Exposure in Young Patients With Retinoblastoma and in Their Parents and Young Healthy Unrelated Volunteers

Condition: Retinoblastoma
Interventions: Genetic: DNA ploidy analysis; Genetic: DNA stability analysis; Genetic: Southern blotting; Genetic: genetic linkage analysis; Genetic: loss of heterozygosity analysis; Genetic: mutation analysis; Genetic: polymorphism analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: evaluation of cancer risk factors; Procedure: mutation carrier screening
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Phase II Study of AZD2281 in Known BRCA or Recurrent High Grade Ovarian Cancer or Known BRCA/ Triple Neg Breast Cancer

Conditions: Ovarian Carcinoma; Breast Cancer
Intervention: Drug: AZD2281
Sponsors: AstraZeneca; British Columbia Cancer Agency
Active, not recruiting - verified March 2010
Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy

Condition: Brain and Central Nervous System Tumors
Intervention: Drug: cilengitide
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib

Conditions: ErbB2 (HER2) Amplified Gastric; Esophageal; or Gastro-esophageal Junction Adenocarcinoma That is Unresectable Due to Locally Advanced Metastatic, or Locally Recurrent Disease.
Intervention: Drug: Lapatinib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer

Condition: Kidney Neoplasms
Interventions: Drug: Axitinib (AG-013736); Drug: Sorafenib
Sponsor: Pfizer
Recruiting - verified March 2010
Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy

Condition: Prostatic Neoplasms
Interventions: Drug: Prednisone; Drug: sunitinib; Drug: Placebo; Drug: Prednisone
Sponsor: Pfizer
Recruiting - verified March 2010
Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy

Conditions: Prevention of Venous Thromboembolism; Cancer
Interventions: Drug: AVE5026; Drug: Placebo
Sponsor: Sanofi-Aventis
Recruiting - verified March 2010
Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia Patients With Low MGMT Expression (Study P05052)

Condition: Leukemia, Myeloid, Acute
Intervention: Drug: Temozolomide
Sponsor: Schering-Plough
Recruiting - verified March 2010
Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer

Conditions: Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carcinoma, Adenosquamous Cell
Interventions: Drug: CP 751,871 (Figitumumab) and Erlotinib; Drug: Erlotinib
Sponsor: Pfizer
Terminated - verified March 2010
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer

Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: daunorubicin hydrochloride; Other: pharmacological study; Procedure: dual x-ray absorptometry
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Suspended - verified March 2010
Evaluating Dactinomycin and Vincristine in Young Patients With Cancer

Conditions: Kidney Cancer; Leukemia; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Biological: dactinomycin; Drug: vincristine sulfate; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: liquid chromatography; Other: mass spectrometry; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: docetaxel; Drug: lapatinib ditosylate; Drug: paclitaxel; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment
Sponsors: NCIC Clinical Trials Group; GlaxoSmithKline
Recruiting - verified July 2009
A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer

Conditions: Hedgehog Pathway; Smoothened; Basal Cell Carcinoma (BCC); Basal Cell Nevoid Syndrome (BCNS)
Intervention: Drug: BMS-833923 (XL139)
Sponsors: Bristol-Myers Squibb; Exelixis
Recruiting - verified October 2009
Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Biliary Cancer

Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Liver Cancer
Interventions: Drug: capecitabine; Drug: gemcitabine hydrochloride; Procedure: quality-of-life assessment
Sponsor: NCIC Clinical Trials Group
Active, not recruiting - verified March 2010
Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG-2402

Conditions: Breast Cancer; Cognitive/Functional Effects; Fatigue; Psychosocial Effects of Cancer and Its Treatment; Sleep Disorders
Interventions: Procedure: assessment of therapy complications; Procedure: cognitive assessment; Procedure: fatigue assessment and management; Procedure: psychosocial assessment and care
Sponsors: International Breast Cancer Study Group; National Cancer Institute (NCI); Australian New Zealand Breast Cancer Trials Group; Cancer and Leukemia Group B
Recruiting - verified March 2010
Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Drug: bortezomib; Drug: cytarabine; Drug: etoposide phosphate; Drug: idarubicin
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer

Condition: Esophageal Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: paclitaxel; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: placebo; Drug: BIBW 2992
Sponsor: Boehringer Ingelheim Pharmaceuticals
Active, not recruiting - verified March 2010
Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: etoposide phosphate; Drug: methotrexate; Drug: thiotepa; Drug: vincristine sulfate; Genetic: mutation analysis; Other: immunohistochemistry staining method; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: 3-dimensional conformal radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Suspended - verified March 2010
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Drug: erlotinib [Tarceva]; Drug: erlotinib [Tarceva]; Drug: gemcitabine
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Cetuximab With or Without Brivanib in Treating Patients With Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Biological: cetuximab; Drug: brivanib alaninate; Other: laboratory biomarker analysis
Sponsor: NCIC Clinical Trials Group
Recruiting - verified March 2010
Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: midostaurin; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Dose Escalation Study of MK1775 in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors

Condition: Solid Tumors
Interventions: Drug: Comparator: MK1775; Drug: Comparator: gemcitabine; Drug: Comparator: cisplatin; Drug: Comparator: carboplatin; Drug: Comparator: MK1775; Drug: Comparator: MK1775; Drug: Comparator: MK1775; Drug: Comparator: MK1775; Drug: Comparator: gemcitabine; Drug: Comparator: cisplatin; Drug: Comparator: carboplatin; Drug: Comparator: gemcitabine; Drug: Comparator: cisplatin; Drug: Comparator: carboplatin
Sponsor: Merck
Recruiting - verified March 2010
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types

Conditions: Advanced Non-Small Cell Lung Cancer; Transitional Cell Carcinoma; Soft Tissue Sarcoma; Gastric/Esophageal Adenocarcinoma; Pancreatic Cancer Including Ampulla of Vater
Interventions: Drug: brivanib; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
A Study of R1507 in Patients With Recurrent or Refractory Sarcoma.

Condition: Sarcoma
Intervention: Drug: RG1507
Sponsors: Hoffmann-La Roche; Sarcoma Alliance for Research through Collaboration
Active, not recruiting - verified February 2010
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma

Condition: High Risk Stage III Melanoma
Interventions: Drug: ipilimumab; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer

Conditions: Breast Cancer; Breast Tumors; Metastatic Cancer
Interventions: Drug: AMG 479 or placebo administered with either exemestane or fulvestrant; Drug: AMG 479 or placebo administered with either exemestane or fulvestrant; Drug: AMG 479 or placebo administered with either exemestane or fulvestrant
Sponsor: Amgen
Active, not recruiting - verified March 2010
Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer

Condition: Urinary Bladder Neoplasms
Interventions: Drug: larotaxel (XRP9881); Drug: gemcitabine; Drug: cisplatin
Sponsor: Sanofi-Aventis
Active, not recruiting - verified February 2010
Sorafenib Long Term Extension Program (STEP)

Condition: Neoplasms
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
Sponsors: Bayer; ICON Clinical Research
Recruiting - verified March 2010
Radiation Therapy With or Without Temozolomide in Treating Patients With Anaplastic Glioma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: temozolomide; Genetic: DNA methylation analysis; Other: laboratory biomarker analysis; Procedure: adjuvant therapy; Procedure: quality-of-life assessment; Radiation: radiation therapy
Sponsors: European Organization for Research and Treatment of Cancer; NCIC Clinical Trials Group; Radiation Therapy Oncology Group; Medical Research Council
Recruiting - verified March 2010
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors

Conditions: Melanoma; Lung Cancer; Renal Cell Carcinoma; Squamous Cell Carcinoma of the Head and Neck
Intervention: Drug: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
Sponsor: Jennerex Biotherapeutics
Active, not recruiting - verified February 2010
A Study Combining FOLFOX or FOLFIRI With AG-013736 or Avastin in Patients With Metastatic Colorectal Cancer After Failure of One First Line Regimen.

Condition: Colorectal Neoplasms
Interventions: Drug: bevacizumab; Drug: AG-013736 (axitinib); Drug: AG-013736 (axitinib); Drug: bevacizumab
Sponsor: Pfizer
Active, not recruiting - verified March 2010
A Phase III Trial of ZD4054 (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: ZD4054; Drug: Luteinising hormone-releasing hormone analogue (LHRHa); Drug: Megace; Drug: Estradiol; Drug: Prednisolone; Drug: Ketoconazole; Drug: Docetaxel
Sponsor: AstraZeneca
Recruiting - verified February 2010
A Phase III Trial of ZD4054 (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Docetaxel; Drug: ZD4054
Sponsor: AstraZeneca
Recruiting - verified February 2010
Laparoscopic Approach to Cervical Cancer

Condition: Cervical Cancer
Interventions: Procedure: Total Abdominal Radical Hysterectomy; Procedure: Total Laparoscopic or Robotic Radical Hysterectomy
Sponsors: Queensland Centre for Gynaecological Cancer; M.D. Anderson Cancer Center
Recruiting - verified February 2010
Phase II, 2nd Line Melanoma - RAND Monotherapy

Condition: Melanoma
Intervention: Drug: Anti-CD137 (4-1BB) (BMS-663513)
Sponsor: Bristol-Myers Squibb
Completed - verified January 2010
Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Conditions: MDS; Myelodysplastic Syndromes; Thrombocytopenia
Interventions: Drug: Placebo; Biological: Romiplostim
Sponsor: Amgen
Recruiting - verified March 2010
A Study to Determine the Activity of SCH 717454 in Subjects With Relapsed Osteosarcoma or Ewing's Sarcoma (Study P04720AM3)

Conditions: Osteosarcoma; Sarcoma, Ewing's; Peripheral Neuroectodermal Tumor
Interventions: Drug: SCH 717454 (19D12); Drug: SCH 717454 (19D12)
Sponsor: Schering-Plough
Recruiting - verified February 2010
Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

Condition: Leukemia
Interventions: Biological: rituximab; Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: lenalidomide
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical Trials Group; Southwest Oncology Group
Recruiting - verified March 2010
Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women

Condition: Hypoactive Sexual Desire Disorder
Interventions: Drug: testosterone gel; Drug: placebo gel
Sponsor: BioSante Pharmaceuticals
Recruiting - verified February 2010
Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology

Conditions: Carcinoma, Squamous Cell; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung
Interventions: Drug: CP-751,871 + Carboplatin +Paclitaxel; Drug: Carboplatin + Paclitaxel
Sponsor: Pfizer
Terminated - verified February 2010
Image-Guided Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Shoulder, Arm, Hip, or Leg

Conditions: Lymphedema; Musculoskeletal Complications; Radiation Fibrosis; Radiation Toxicity; Sarcoma
Interventions: Drug: chemotherapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2010
GAUSS: A Study of RO5072759 in Patients With Indolent Non-Hodgkin's Lymphoma

Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: RO5072759; Drug: rituximab
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising PSA After Surgery for Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: flutamide; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified March 2010
Treatment of Localized Prostate Cancer With High Intensity Focused Ultrasound Using the Sonablate® 500 System in Canada

Condition: Prostate Cancer
Intervention: Device: Sonablate 500 (SB-500)
Sponsor: USHIFU, LLC
Not yet recruiting - verified March 2010
Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors

Conditions: Cognitive/Functional Effects; Metastatic Cancer; Neurotoxicity; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: memantine hydrochloride; Other: placebo; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma

Condition: Neuroblastoma
Interventions: Drug: carboplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: melphalan; Drug: thiotepa
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Suspended - verified March 2010
Panitumumab DDI Irinotecan

Condition: Metastatic Colorectal Cancer
Interventions: Drug: Panitumumab; Drug: Irinotecan
Sponsor: Amgen
Active, not recruiting - verified February 2010
Efficacy Study of ABR-215050 to Treat Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: ABR-215050, tasquinimod; Drug: Placebo
Sponsor: Active Biotech Research
Active, not recruiting - verified March 2010
Phase I Study of Sorafenib Dosed Continuously With Cyclophosphamide and Doxorubicin

Condition: Cancer
Intervention: Drug: Nexavar (Sorafenib, BAY43-9006)
Sponsor: Bayer
Active, not recruiting - verified February 2010
A Phase 1 Study Testing CP-675,206 In Combination With Gemcitabine In Patients With Previously Untreated, Advanced Pancreatic Cancer

Condition: Pancreatic Cancer
Intervention: Drug: CP-675,206 and gemcitabine
Sponsor: Pfizer
Recruiting - verified February 2010
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer

Condition: Inflammatory Breast Cancer
Interventions: Drug: lapatinib (Tykerb); Drug: pazopanib (GW786034); Drug: Pazopanib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors

Condition: Ewing's Sarcoma Family of Tumors
Intervention: Drug: CP-751,871
Sponsor: Pfizer
Active, not recruiting - verified March 2010
Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: lestaurtinib; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: methylprednisolone; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma

Condition: Retinoblastoma
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: thiotepa; Drug: vincristine sulfate; Procedure: autologous bone marrow transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study

Conditions: Early Breast Cancer; ErbB2+
Interventions: Drug: Lapatinib; Biological: Trastuzumab
Sponsor: GlaxoSmithKline
Active, not recruiting - verified February 2010
Pertuzumab and Cetuximab in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Cetuximab

Condition: Colorectal Cancer
Interventions: Biological: cetuximab; Biological: pertuzumab; Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: Dana-Farber Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified December 2008
Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed By Surgery

Condition: Lung Cancer
Interventions: Procedure: conventional surgery; Radiation: stereotactic body radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia

Condition: Leukemia
Interventions: Biological: anti-thymocyte globulin; Drug: busulfan; Drug: cyclophosphamide; Drug: cyclosporine; Drug: methotrexate; Drug: methylprednisolone; Drug: tacrolimus; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: allogeneic bone marrow transplantation
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 2)

Condition: Advanced Solid Tumors
Intervention: Drug: Epofolate
Sponsor: Bristol-Myers Squibb
Active, not recruiting - verified February 2010
A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.

Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: Herceptin; Drug: docetaxel
Sponsor: Hoffmann-La Roche
Active, not recruiting - verified February 2010
A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse

Condition: Multiple Myeloma
Interventions: Drug: Tanespimycin; Drug: Bortezomib
Sponsor: Bristol-Myers Squibb
Suspended - verified April 2009
Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bios' HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs

Conditions: Papillomavirus Infection; Cervical Cancer
Intervention: Biological: Cervarix TM
Sponsor: GlaxoSmithKline
Active, not recruiting - verified February 2010
AZD2281 and Irinotecan in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Drug: irinotecan hydrochloride; Drug: olaparib; Other: pharmacological study
Sponsor: NCIC Clinical Trials Group
Recruiting - verified March 2010
High-Dose or Standard-Dose Radiation Therapy and Chemotherapy in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Conditions: Lung Cancer; Radiation Toxicity
Interventions: Biological: cetuximab; Drug: carboplatin; Drug: paclitaxel; Radiation: 3-dimensional conformal radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Cancer and Leukemia Group B
Recruiting - verified March 2010
A Phase 1b/2 Study of AMG 655 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Drug: AMG 655; Other: AMG 655 placebo
Sponsor: Amgen
Active, not recruiting - verified February 2010
A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors

Conditions: Mesothelioma; Non-small Cell Lung Cancer; Neoplasms
Intervention: Drug: Sunitinib, Pemetrexed, Cisplatin, Carboplatin
Sponsor: Pfizer
Active, not recruiting - verified March 2010
Study of Addition of Panitumumab to Chemoradiation Therapy in Subjects With Locally Advanced Head and Neck Cancer

Conditions: Head and Neck Cancer; Squamous Cell Carcinoma
Interventions: Drug: Cisplatin; Radiation: Standard Fractionation Radiotherapy; Drug: Panitumumab; Drug: Cisplatin
Sponsor: Amgen
Active, not recruiting - verified February 2010
Observation or Radical Treatment in Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Other: active surveillance; Procedure: conventional surgery; Procedure: quality-of-life assessment; Radiation: brachytherapy; Radiation: radiation therapy
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI); Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; Southwest Oncology Group
Recruiting - verified March 2010
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Procedure: thoracoscopic surgery; Procedure: videothoracoscopy
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group; American College of Surgeons; Southwest Oncology Group
Recruiting - verified March 2010
Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma

Condition: Neuroblastoma
Interventions: Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: topotecan hydrochloride
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

Condition: Breast Cancer
Interventions: Biological: Trastuzumab; Drug: Lapatinib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer

Conditions: Ovarian Cancer; Primary Peritoneal Cancer
Interventions: Drug: pemetrexed; Drug: carboplatin
Sponsor: Eli Lilly and Company
Completed - verified March 2010
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer

Condition: Invasive Breast Cancer
Interventions: Drug: doxorubicin; Drug: cyclophosphamide; Drug: paclitaxel; Drug: trastuzumab; Drug: lapatinib
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); GlaxoSmithKline
Recruiting - verified February 2010
Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer

Condition: Neoplasms
Interventions: Drug: OGX-427; Drug: Docetaxel
Sponsor: OncoGenex Technologies
Recruiting - verified February 2010
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer

Condition: Tumor Antigen-positive Non-Small Cell Lung Cancer
Interventions: Biological: GSK1572932A Antigen-Specific Cancer Immunotherapeutic; Biological: Placebo Control
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Risk-Group Classification of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Genetic: DNA ploidy analysis; Genetic: chromosomal translocation analysis; Genetic: fluorescence in situ hybridization; Genetic: polymorphism analysis; Other: immunologic technique; Other: laboratory biomarker analysis; Procedure: biopsy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: trastuzumab [Herceptin]; Drug: Taxane (docetaxel or paclitaxel)
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Temsirolimus Versus Sorafenib as Second-Line Therapy in Patients With Advanced RCC Who Have Failed First-Line Sunitinib

Condition: Renal Cell Carcinoma
Interventions: Drug: Temsirolimus; Drug: Sorafenib
Sponsor: Wyeth
Recruiting - verified February 2010
Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.

Condition: Carcinoma, Pancreatic Ductal
Interventions: Drug: AG-013736; Drug: Gemcitabine; Drug: Gemcitabine; Drug: placebo
Sponsor: Pfizer
Active, not recruiting - verified March 2010
Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors

Conditions: Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Ovarian Cancer; Testicular Germ Cell Tumor
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: ifosfamide; Drug: paclitaxel
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
SPECTRUM: Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer

Condition: Recurrent and/or Metastatic Head and Neck Cancer
Interventions: Drug: ARM 1; Drug: ARM 2
Sponsor: Amgen
Active, not recruiting - verified February 2010
MONET1-MOtesanib NSCLC Efficacy and Tolerability Study

Condition: Non-small Cell Lung Cancer
Interventions: Drug: AMG 706; Drug: placebo
Sponsors: Amgen; Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin

Conditions: Ototoxicity; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Procedure: management of therapy complications
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
First Line Therapy for Patients With Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Intervention: Drug: ABI-007
Sponsor: Abraxis BioScience Inc.
Recruiting - verified January 2010
A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone

Condition: Carcinoma, Non-Small Cell Lung
Interventions: Drug: erlotinib; Drug: sunitinib; Drug: erlotinib; Drug: placebo
Sponsor: Pfizer
Active, not recruiting - verified March 2010
Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer

Condition: Colorectal Neoplasms
Interventions: Drug: 5 fluorouracil; Drug: irinotecan; Drug: levo- leucovorin; Drug: sunitinib; Drug: 5 fluorouracil; Drug: irinotecan; Drug: levo- leucovorin; Drug: placebo
Sponsor: Pfizer
Completed - verified March 2010
A Study of Avastin (Bevacizumab) Plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.

Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Taxane-based chemotherapy
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
MRI Targeted Focal Laser Thermal Therapy of Biopsy Confirmed Prostate Cancer

Condition: Prostate Cancer
Intervention: Procedure: MRI Targeted Focal Thermal Therapy of Prostate Cancer
Sponsor: University Health Network, Toronto
Active, not recruiting - verified December 2006
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases

Conditions: Leukemia; Myelodysplastic Syndromes
Intervention: Procedure: allogeneic bone marrow transplantation
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Suspended - verified March 2010
A Phase I/II Study of HKI-272 in Combination With Paclitaxel in Subjects With Advanced Solid Tumors and Breast Cancer

Conditions: Advanced Breast Cancer; Advanced Malignant Solid Tumors; Breast Neoplasms
Intervention: Drug: HKI-272
Sponsor: Wyeth
Active, not recruiting - verified February 2010
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.

Condition: Neoplasms
Intervention: Drug: SU011248
Sponsor: Pfizer
Recruiting - verified March 2010
Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases

Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Myelodysplastic Syndromes; Secondary Myelofibrosis
Interventions: Biological: filgrastim; Procedure: allogeneic bone marrow transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: The Canadian Blood and Marrow Transplant Group; National Cancer Institute (NCI)
Recruiting - verified July 2009
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia

Conditions: Cognitive/Functional Effects; Leukemia; Long-term Effects Secondary to Cancer Therapy in Children; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment
Interventions: Genetic: microarray analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: cognitive assessment; Procedure: diffusion tensor imaging; Procedure: management of therapy complications; Procedure: psychosocial assessment and care
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer

Condition: Breast Neoplasms
Interventions: Drug: Sunitinib + Capecitabine; Drug: Capecitabine
Sponsor: Pfizer
Active, not recruiting - verified March 2010
Brain Metastases In ErbB2-Positive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: lapatinib plus capecitabine; Drug: lapatinib plus topotecan
Sponsor: GlaxoSmithKline
Terminated - verified February 2010
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: docetaxel; Drug: goserelin; Drug: leuprolide acetate; Procedure: conventional surgery
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical Trials Group
Recruiting - verified March 2010
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

Conditions: Carcinoma, Renal Cell; Breast Neoplasms; Carcinoma, Islet Cell; Gastrointestinal Stromal Tumors
Intervention: Drug: sunitinib
Sponsor: Pfizer
Active, not recruiting - verified March 2010
Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma

Condition: Lymphoma
Interventions: Biological: rituximab; Drug: bortezomib; Drug: cyclophosphamide; Drug: prednisone; Drug: vincristine sulfate
Sponsor: NCIC Clinical Trials Group
Active, not recruiting - verified March 2010
Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: dasatinib; Genetic: gene expression analysis; Genetic: mutation analysis; Other: immunohistochemistry staining method; Other: immunologic technique; Other: liquid chromatography; Other: mass spectrometry; Other: pharmacological study; Procedure: biopsy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Phase I Study of BMS-690514 in Combination With Paclitaxel and Carboplatin

Condition: Cancer (Solid Tumors)
Intervention: Drug: BMS-690514
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer

Conditions: Neoplasms; Prostatic Neoplasms
Interventions: Drug: cabazitaxel (XRP6258) (RPR116258); Drug: mitoxantrone; Drug: prednisone
Sponsor: Sanofi-Aventis
Completed - verified March 2010
Dose/ Schedule Finding Trial of AMG 531 for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)

Conditions: Lung Cancer; Chemotherapy-Induced Thrombocytopenia; Non-small Cell Lung Cancer; Cancer; Lung Neoplasms; Oncology; Solid Tumors; Thrombocytopenia
Interventions: Biological: AMG 531; Drug: Placebo
Sponsor: Amgen
Completed - verified February 2010
Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: gemcitabine hydrochloride; Procedure: conventional surgery
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified March 2010
Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors

Conditions: Endometrial Cancer; Ovarian Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: carboplatin; Drug: paclitaxel; Drug: temsirolimus
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI)
Active, not recruiting - verified March 2010
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: nelarabine; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer

Condition: Esophageal Cancer
Interventions: Drug: Irinotecan; Drug: Cisplatin; Procedure: Radiation; Procedure: Surgery; Drug: sunitinib (Sutent)
Sponsors: University Health Network, Toronto; Pfizer
Recruiting - verified March 2010
Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer

Condition: Breast Neoplasms
Interventions: Drug: Sunitinib malate; Drug: Taxotere
Sponsor: Pfizer
Active, not recruiting - verified March 2010
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: isotretinoin; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.

Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Herceptin; Drug: Docetaxel
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer

Condition: Brain Metastases From Non-small Cell Lung Cancer
Intervention: Drug: HYCAMTIN, oral capsules
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Sunitinib in Treating Patients With Unresectable, Locally Advanced or Metastatic Cervical Cancer

Condition: Cervical Cancer
Intervention: Drug: sunitinib malate
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI)
Active, not recruiting - verified March 2010
Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma

Condition: Malignant Mesothelioma
Intervention: Drug: sunitinib malate
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI)
Suspended - verified March 2010
Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma

Condition: Lymphoma
Intervention: Drug: sunitinib malate
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI)
Active, not recruiting - verified March 2010
Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation Therapy for Non-small Cell Lung Cancer (PEARL)

Condition: Non-small Cell Lung Cancer
Intervention: Drug: Erlotinib
Sponsors: Ontario Clinical Oncology Group (OCOG); Roche Pharma AG
Recruiting - verified February 2010
Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer

Condition: Thyroid Neoplasms
Intervention: Drug: AG-013736
Sponsor: Pfizer
Active, not recruiting - verified March 2010
Sunitinib in Treating Patients With Advanced or Metastatic Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Intervention: Drug: sunitinib malate
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI)
Active, not recruiting - verified March 2010
AT7519M in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory Non-Hodgkin's Lymphoma

Conditions: Lymphoma; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: CDKI AT7519; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: biopsy
Sponsor: NCIC Clinical Trials Group
Recruiting - verified March 2010
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor

Condition: Kidney Cancer
Interventions: Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study To Evaluate Pregabalin In The Treatment Of Moderate To Severe Chronic Bone Pain Related To Metastatic Cancer

Conditions: Bone Neoplasms; Pain, Intractable; Cancer
Interventions: Drug: Pregabalin; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission

Conditions: Graft Versus Host Disease; Leukemia
Interventions: Drug: methotrexate; Drug: sirolimus; Drug: tacrolimus
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

Conditions: Breast Cancer; Cognitive/Functional Effects; Lung Cancer; Metastatic Cancer; Prostate Cancer
Interventions: Radiation: radiation therapy; Radiation: stereotactic radiosurgery
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI); American College of Surgeons; Eastern Cooperative Oncology Group; Radiation Therapy Oncology Group
Recruiting - verified March 2010
RADIANT: A Study of Tarceva After Surgery With or Without Adjuvant Chemotherapy in NSCLC Patients Who Have EGFR-positive Tumors

Condition: Non-small Cell Lung Cancer
Interventions: Drug: Tarceva; Drug: Placebo
Sponsor: OSI Pharmaceuticals
Active, not recruiting - verified October 2009
Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer

Condition: Breast Cancer
Intervention: Drug: lapatinib
Sponsor: GlaxoSmithKline
Active, not recruiting - verified March 2010
AEG35156 and Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Solid Tumors

Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: AEG35156; Drug: docetaxel; Genetic: protein expression analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: flow cytometry; Other: immunoenzyme technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: biopsy
Sponsor: NCIC Clinical Trials Group
Active, not recruiting - verified March 2010
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer

Condition: Breast Neoplasms
Interventions: Drug: CP-751,871 + exemestane; Drug: exemestane
Sponsors: Pfizer; Massachusetts General Hospital
Recruiting - verified March 2010
Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: gemtuzumab ozogamicin; Drug: mitoxantrone hydrochloride
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: clofarabine; Drug: cytarabine; Drug: methotrexate; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Endobronchial Ultrasound vs Mediastinoscopy in NSCLC

Condition: Non-small Cell Lung Cancer
Intervention: Procedure: Endobronchial Ultrasound Guided Transthoracic Needle Biopsy
Sponsor: University Health Network, Toronto
Recruiting - verified March 2010
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes

Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Drug: asparaginase; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: thioguanine
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men

Condition: Prostate Cancer
Interventions: Drug: Dutasteride; Drug: Matching placebo
Sponsor: GlaxoSmithKline
Active, not recruiting - verified March 2010
PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy

Condition: Metastatic Colorectal Cancer
Interventions: Drug: 5-Fluorouracil, Oxaliplatin, Leucovorin; Drug: 5-Fluorouracil, Oxaliplatin, Leucovorin, Panitumumab
Sponsor: Amgen
Active, not recruiting - verified February 2010
Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer)

Condition: Non-small Cell Lung Cancer
Intervention: Drug: BMS-275183 (oral taxane)
Sponsor: Bristol-Myers Squibb
Terminated - verified September 2007
A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer

Conditions: Breast Neoplasms; Breast Tumors; Breast Cancer; Locally Recurrent and Metastatic Breast Cancer
Interventions: Drug: AMG 706 placebo; Drug: Bevacizumab; Drug: AMG 706
Sponsor: Amgen
Active, not recruiting - verified February 2010
AEG35156 and Docetaxel in Treating Patients With Solid Tumors

Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: AEG35156; Drug: docetaxel; Other: pharmacological study
Sponsor: NCIC Clinical Trials Group
Active, not recruiting - verified March 2010
An Open Label Treatment Extension Study of AMG 706

Condition: Solid Tumors
Intervention: Drug: AMG 706
Sponsor: Amgen
Active, not recruiting - verified February 2010
Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor

Condition: Kidney Cancer
Interventions: Biological: dactinomycin; Drug: doxorubicin hydrochloride; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer

Condition: Bladder Cancer
Interventions: Biological: BCG vaccine; Drug: gefitinib; Procedure: quality-of-life assessment
Sponsor: NCIC Clinical Trials Group
Active, not recruiting - verified March 2010
High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma

Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified October 2008
Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma

Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: cyclophosphamide; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma

Condition: Lymphoma
Interventions: Biological: monoclonal antibody SGN-30; Drug: carboplatin; Drug: cytarabine; Drug: etoposide; Drug: ifosfamide; Drug: methotrexate; Drug: therapeutic hydrocortisone
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified May 2009
PXD101 and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Drug: azacitidine; Drug: belinostat
Sponsors: University of Chicago; National Cancer Institute (NCI)
Recruiting - verified April 2009
Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Condition: Lung Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: hypofractionated radiation therapy
Sponsor: NCIC Clinical Trials Group
Active, not recruiting - verified March 2010
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma

Conditions: Childhood Malignant Fibrous Histiocytoma of Bone; Sarcoma
Interventions: Drug: doxorubicin hydrochloride; Drug: ifosfamide; Other: clinical observation; Procedure: therapeutic conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
AZD2171 and Standard Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer or Colorectal Cancer

Conditions: Colorectal Cancer; Lung Cancer
Interventions: Drug: cediranib maleate; Drug: cisplatin; Drug: fluorouracil; Drug: gemcitabine hydrochloride; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

Conditions: Leukemia; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Drug: sorafenib tosylate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors

Condition: Kidney Cancer
Interventions: Biological: dactinomycin; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: thiotepa; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: bevacizumab [Avastin]; Drug: Placebo; Drug: Docetaxel
Sponsor: Hoffmann-La Roche
Active, not recruiting - verified February 2010
The Second Multicenter Hemophilia Cohort Study

Conditions: Liver Decompensation; Hepatocellular Carcinoma; Non-Hodgkin Lymphoma
Intervention:
Sponsors: National Cancer Institute (NCI); Multicenter Hemophilia Cohort Study
Completed - verified March 2010
Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma

Condition: Retinoblastoma
Interventions: Drug: carboplatin; Drug: etoposide; Drug: vincristine sulfate; Other: clinical observation
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Double-blind Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Metastases in Subjects With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

Condition: Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
Interventions: Drug: Zoledronic Acid; Biological: Denosumab
Sponsor: Amgen
Active, not recruiting - verified March 2010
PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin

Condition: Non Hodgkin Lymphoma
Interventions: Drug: enzastaurin; Drug: placebo
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Sunitinib or Sorafenib in Treating Patients With Kidney Cancer That Was Removed By Surgery

Condition: Kidney Cancer
Interventions: Drug: sorafenib tosylate; Drug: sunitinib malate; Other: placebo
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B; Southwest Oncology Group; NCIC Clinical Trials Group
Recruiting - verified March 2010
Study to Evaluate Safety and Feasibility of Using OGX-011 in Combination With Second Line Chemotherapy in Patients With HRPC

Condition: Prostate Cancer
Interventions: Drug: Docetaxel; Drug: Prednisone; Drug: OGX-011
Sponsor: OncoGenex Technologies
Active, not recruiting - verified June 2009
A Phase I Study of BMS-690514 in Patients With Advanced or Metastatic Solid Tumors

Conditions: Cancer; Tumor
Intervention: Drug: BMS-690514
Sponsor: Bristol-Myers Squibb
Completed - verified August 2009
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery

Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Drug: vinorelbine ditartrate
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; North Central Cancer Treatment Group
Recruiting - verified March 2010
Double-blind Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Metastases in Men With Hormone-refractory Prostate Cancer

Condition: Bone Metastases in Men With Hormone-Refractory Prostate Cancer
Interventions: Drug: denosumab; Drug: zoledronic acid
Sponsor: Amgen
Active, not recruiting - verified March 2010
A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.

Condition: Bone Metastases in Subjects With Advanced Breast Cancer
Interventions: Biological: Denosumab; Drug: Zoledronic Acid
Sponsors: Amgen; Daiichi Sankyo Inc.
Active, not recruiting - verified March 2010
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma

Condition: Melanoma
Interventions: Drug: Ipilimumab and Dacarbazine; Drug: Placebo and Dacarbazine
Sponsors: Bristol-Myers Squibb; Medarex
Active, not recruiting - verified March 2010
A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer

Conditions: Thrombosis; Cancer; Pulmonary Embolism
Interventions: Drug: Apixaban; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Ontario Clinical Oncology Group
Completed - verified May 2009
Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Lapatinib; Biological: Trastuzumab
Sponsor: GlaxoSmithKline
Completed - verified March 2010
Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)

Condition: Prostatic Neoplasms
Interventions: Drug: CP-751,871; Drug: docetaxel; Drug: prednisone; Drug: docetaxel; Drug: prednisone
Sponsor: Pfizer
Active, not recruiting - verified March 2010
Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC)

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: CP-675,206; Drug: best supportive care
Sponsor: Pfizer
Active, not recruiting - verified February 2010
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)

Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: chemotherapy; Drug: exemestane; Drug: letrozole; Drug: tamoxifen citrate
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; American College of Surgeons; North Central Cancer Treatment Group; NCIC Clinical Trials Group; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified March 2010
Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer

Conditions: Prostate Cancer; Pancreatic Cancer; Non-Small-Cell Lung Cancer
Intervention: Drug: Nadroparin
Sponsor: GlaxoSmithKline
Completed - verified February 2010
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant

Conditions: Kidney Cancer; Leukemia; Lymphoma; Myelodysplastic Syndromes; Neuroblastoma; Pulmonary Complications; Sarcoma
Interventions: Biological: etanercept; Drug: methylprednisolone
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: Bortezomib + Rituximab; Drug: Rituximab
Sponsors: Millennium Pharmaceuticals, Inc.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Active, not recruiting - verified February 2010
Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma

Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: dexamethasone; Drug: lenalidomide; Drug: melphalan
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
PROFIT - Prostate Fractionated Irradiation Trial

Condition: Prostate Cancer
Interventions: Procedure: 7800 cGy/39 fractions in 8 weeks; Procedure: 6000 cGy/20 fractions in 4 weeks
Sponsors: Ontario Clinical Oncology Group (OCOG); Canadian Institutes of Health Research (CIHR); Trans-Tasman Radiation Oncology Group (TROG)
Recruiting - verified February 2010
Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor

Condition: Adrenocortical Carcinoma
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: mitotane; Procedure: conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
AZD2171 in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery

Condition: Malignant Mesothelioma
Interventions: Drug: cediranib maleate; Other: laboratory biomarker analysis
Sponsors: University of Chicago; National Cancer Institute (NCI)
Recruiting - verified June 2007
Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older

Condition: Prophylaxis for HPV Infections and Associated Cervical Neoplasia
Interventions: Biological: Cervarix; Biological: Placebo control
Sponsor: GlaxoSmithKline
Active, not recruiting - verified March 2010
Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer

Condition: Prostate Cancer
Intervention: Device: Integrated Imaging High Intensity Focused Ultrasound
Sponsor: EDAP TMS S.A.
Recruiting - verified February 2010
Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer

Condition: Hormone Refractory Prostate Cancer
Interventions: Biological: denosumab; Biological: Placebo
Sponsor: Amgen
Active, not recruiting - verified March 2010
Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

Condition: Melanoma
Interventions: Drug: ipilimumab (MDX-010, BMS-734016); Drug: Ipilimumab; Drug: Ipilimumab
Sponsors: Bristol-Myers Squibb; Medarex
Completed - verified January 2009
RAPID: Randomized Trial of Accelerated Partial Breast Irradiation

Condition: Breast Cancer
Interventions: Radiation: 3D-CRT APBI; Radiation: WBI
Sponsors: Ontario Clinical Oncology Group (OCOG); Canadian Institutes of Health Research (CIHR); Canadian Breast Cancer Research Alliance
Recruiting - verified March 2010
Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer

Conditions: Head and Neck Cancer; Radiation Toxicity
Interventions: Drug: amifostine trihydrate; Drug: cisplatin; Drug: fluorouracil; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
AZD0530 and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery

Condition: Pancreatic Cancer
Interventions: Drug: AZD0530; Drug: gemcitabine hydrochloride
Sponsor: NCIC Clinical Trials Group
Active, not recruiting - verified March 2010
Study to Assess Compliance With Long-Term Mercaptopurine Treatment in Young Patients With Acute Lymphoblastic Leukemia in Remission

Condition: Leukemia
Interventions: Behavioral: compliance monitoring; Drug: mercaptopurine; Drug: methotrexate; Other: study of socioeconomic and demographic variables
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: erlotinib; Drug: sunitinib; Drug: erlotinib; Drug: placebo
Sponsor: Pfizer
Active, not recruiting - verified March 2010
Docetaxel and Prednisone With or Without OGX-011 in Treating Patients With Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy

Condition: Prostate Cancer
Interventions: Drug: custirsen sodium; Drug: docetaxel; Drug: prednisone
Sponsor: NCIC Clinical Trials Group
Active, not recruiting - verified March 2010
OGX-011 and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: custirsen sodium; Drug: docetaxel
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Aromasin (Exemestane) in Patients With Recurrent or Refractory Stage II - IV Epithelial Ovarian Cancer

Condition: Ovarian Cancer
Intervention: Drug: Exemestane
Sponsor: Ottawa Hospital Research Institute
Completed - verified March 2010
Everolimus in Treating Patients WIth Recurrent or Metastatic Breast Cancer

Condition: Breast Cancer
Intervention: Drug: everolimus
Sponsor: NCIC Clinical Trials Group
Active, not recruiting - verified March 2010
CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy

Condition: Melanoma
Interventions: Drug: dacarbazine or temozolomide (choice); Drug: CP-675,206
Sponsor: Pfizer
Active, not recruiting - verified March 2010
Study of CP-675,206 in Refractory Melanoma

Condition: Refractory Melanoma
Intervention: Drug: CP-675,206
Sponsor: Pfizer
Active, not recruiting - verified February 2010
Paclitaxel and Carboplatin With or Without Cediranib Maleate in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: cediranib maleate; Drug: paclitaxel; Other: placebo
Sponsor: NCIC Clinical Trials Group
Active, not recruiting - verified March 2010
Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer

Condition: Breast Neoplasms
Interventions: Drug: SU011248; Drug: Chemotherapy
Sponsor: Pfizer
Recruiting - verified March 2010
Letrozole in Preventing Breast Cancer in Postmenopausal Women Who Are at Increased Risk for Breast Cancer Due to High Breast Density

Condition: Breast Cancer
Intervention: Drug: letrozole
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Radiation Therapy in Treating Young Patients With Gliomas

Condition: Brain and Central Nervous System Tumors
Intervention: Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

Condition: Bladder Cancer
Interventions: Biological: trastuzumab; Drug: paclitaxel; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2010
Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Other: clinical observation
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies

Condition: Colorectal Cancer
Intervention: Drug: Brivanib + Cetuximab
Sponsor: Bristol-Myers Squibb
Completed - verified March 2009
Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: lenalidomide; Drug: dexamethasone
Sponsors: Celgene Corporation; Prologue Research International
Completed - verified March 2010
A Quality of Life Study re Management of Malignant Pleural Effusions

Condition: Malignant Pleural Effusions
Intervention: Behavioral: LCADLS, FACIT-PAL, FACIT-TS questionnaires
Sponsor: University Health Network, Toronto
Recruiting - verified March 2010
Minimum Dose Computed Tomography of the Thorax for Follow-up in Patients With Resected Lung Carcinoma

Condition: Non-small Cell Lung Cancer
Intervention: Procedure: Minimum Dose Computed Tomography (MnDCT) scan
Sponsor: University Health Network, Toronto
Recruiting - verified March 2010
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies

Condition: Melanoma
Interventions: Drug: Ipilimumab; Drug: Ipilimumab
Sponsor: Bristol-Myers Squibb
Active, not recruiting - verified December 2009
Phase 2 Study of Vinblastine in Children With Recurrent or Refractory Low Grade Glioma

Condition: Glioma
Intervention: Drug: vinblastine sulphate injection
Sponsors: The Hospital for Sick Children; Ontario Cancer Research Network
Active, not recruiting - verified January 2008
Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: CP-751,871 + paclitaxel + carboplatin; Drug: paclitaxel + carboplatin; Drug: CP-751,871 + paclitaxel + carboplatin; Drug: CP-751,871 + paclitaxel + carboplatin + erlotinib; Drug: CP-751,871 + paclitaxel + carboplatin + erlotinib
Sponsor: Pfizer
Recruiting - verified March 2010
Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients

Condition: Familial Adenomatous Polyposis (FAP)
Interventions: Drug: Celecoxib; Other: Routine Medical Care
Sponsor: Pfizer
Terminated - verified March 2010
Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma

Condition: Sarcoma
Interventions: Biological: PEG-interferon alfa-2b; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: methotrexate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI); University College London Hospitals
Recruiting - verified March 2010
A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide

Condition: Malignant Melanoma
Interventions: Drug: Ipilimumab+ Placebo; Drug: Ipilimumab+ Budesonide
Sponsors: Bristol-Myers Squibb; Medarex
Completed - verified August 2008
Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma

Condition: Carcinoma, Renal Cell
Intervention: Drug: sunitinib malate
Sponsor: Pfizer
Active, not recruiting - verified March 2010
Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML

Conditions: Myeloid Leukemia, Chronic, Accelerated Phase; Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Interventions: Drug: dasatinib; Drug: dasatinib; Drug: dasatinib; Drug: dasatinib
Sponsor: Bristol-Myers Squibb
Active, not recruiting - verified September 2009
Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML

Condition: Myeloid Leukemia, Chronic, Chronic-Phase
Interventions: Drug: dasatinib; Drug: dasatinib; Drug: dasatinib; Drug: dasatinib
Sponsor: Bristol-Myers Squibb
Active, not recruiting - verified January 2009
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma

Condition: Lymphoma
Interventions: Drug: cisplatin; Drug: etoposide; Drug: gemcitabine hydrochloride; Drug: methylprednisolone
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin's Disease

Condition: Lymphoma
Interventions: Drug: CHOP regimen; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: prednisone; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer

Conditions: Advanced Breast Cancer; Other Solid Tumors
Interventions: Drug: MK0752, Notch Inhibitor; Drug: MK0752, Notch Inhibitor - 450 mg; Drug: MK0752, Notch Inhibitor - 3 days on, 4 off; Drug: MK0752, Notch Inhibitor - 1 day on, 6 off; Drug: MK0752, Notch Inhibitor - 3 days on, 4 off 350 mg
Sponsor: Merck
Recruiting - verified March 2010
Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer

Condition: Breast Cancer
Intervention: Drug: lapatinib
Sponsor: GlaxoSmithKline
Completed - verified February 2010
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy

Condition: Head and Neck Cancer
Intervention: Drug: bortezomib
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Suspended - verified June 2009
Radiation Therapy in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer

Condition: Breast Cancer
Intervention: Radiation: radiation therapy
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); Radiation Therapy Oncology Group; Southwest Oncology Group
Recruiting - verified March 2010
Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Intervention: Drug: Oral Taxane
Sponsor: Bristol-Myers Squibb
Completed - verified August 2008
Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia

Conditions: Chronic Myeloid Leukemia; Philadelphia-Positive Myeloid Leukemia
Interventions: Drug: Dasatinib; Drug: Imatinib
Sponsor: Bristol-Myers Squibb
Completed - verified February 2010
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

Conditions: Transitional Cell Carcinoma; Bladder Neoplasms; Kidney Neoplasms; Ureter Neoplasms; Bladder Cancer; Neoplasm, Bladder
Intervention: Drug: vinflunine
Sponsors: Bristol-Myers Squibb; Pierre Fabre Medicament
Completed - verified August 2008
Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate

Conditions: Chronic Myeloid Leukemia; Blast Crisis
Intervention: Drug: Dasatinib
Sponsor: Bristol-Myers Squibb
Completed - verified February 2010
Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: tipifarnib
Sponsors: Princess Margaret Hospital, Canada; National Cancer Institute (NCI)
Completed - verified May 2007
Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia

Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Dasatinib
Sponsor: Bristol-Myers Squibb
Completed - verified March 2010
Lapatinib in Treating Patients With Recurrent Glioblastoma Multiforme

Condition: Brain and Central Nervous System Tumors
Intervention: Drug: lapatinib ditosylate
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI)
Active, not recruiting - verified March 2010
Epratuzumab and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: epratuzumab; Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
SB-715992 in Treating Patients With Locally Advanced, Recurrent, or Metastatic Liver Cancer

Condition: Liver Cancer
Intervention: Drug: ispinesib
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI)
Completed - verified March 2010
SB-715992 in Treating Patients With Metastatic or Recurrent Malignant Melanoma

Condition: Melanoma (Skin)
Intervention: Drug: ispinesib
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI)
Completed - verified March 2010
Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes

Condition: Leukemia
Interventions: Biological: filgrastim; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Melanoma

Conditions: Melanoma; Metastases
Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody; Biological: MDX-1379 Melanoma Peptide Vaccine
Sponsor: Bristol-Myers Squibb
Completed - verified March 2010
A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248

Condition: Gastrointestinal Neoplasm
Intervention: Drug: SU011248
Sponsor: Pfizer
Active, not recruiting - verified March 2010
Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: sorafenib tosylate
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI)
Active, not recruiting - verified March 2010
ZD4054 in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)

Condition: Prostate Cancer
Interventions: Drug: ZD4054; Drug: Placebo
Sponsor: AstraZeneca
Completed - verified February 2010
AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer

Conditions: Breast Cancer; Low Bone Mineral Density; Osteopenia
Interventions: Drug: Placebo; Drug: AMG 162 / Denosumab
Sponsor: Amgen
Active, not recruiting - verified March 2010
Diagnostic Procedures in Detecting Tumor Cells in the Bone Marrow of Patients Undergoing Surgery for Stage I, Stage II, or Stage IIIA Breast Cancer

Condition: Breast Cancer
Interventions: Other: immunohistochemistry staining method; Procedure: conventional surgery
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified March 2010
Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: cisplatin; Drug: cyclophosphamide; Drug: lomustine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer

Condition: Breast Cancer
Intervention: Drug: exemestane
Sponsor: NCIC Clinical Trials Group
Recruiting - verified March 2010
Study of Late-Occurring Complications in Childhood Cancer Survivors

Condition: Cancer
Interventions: Genetic: cytogenetic analysis; Genetic: mutation analysis; Genetic: polymorphism analysis; Other: questionnaire administration
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Single-Fraction Radiation Therapy Compared With Multiple-Fraction Reirradiation Therapy in Treating Patients With Painful Bone Metastases

Conditions: Metastatic Cancer; Pain
Intervention: Radiation: radiation therapy
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI); Radiation Therapy Oncology Group; Trans Tasman Radiation Oncology Group at Calvary Mater Newcastle
Recruiting - verified March 2010
Cetuximab and Best Supportive Care Compared With Best Supportive Care Alone in Treating Patients With Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer

Conditions: Colorectal Cancer; Quality of Life
Interventions: Biological: cetuximab; Procedure: quality-of-life assessment
Sponsors: NCIC Clinical Trials Group; Australasian Gastro-Intestinal Trials Group
Completed - verified March 2010
Zoledronate in Preventing Skeletal (Bone)-Related Events in Patients Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases

Conditions: Metastatic Cancer; Prostate Cancer
Interventions: Drug: zoledronic acid; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Southwest Oncology Group; Eastern Cooperative Oncology Group; NCIC Clinical Trials Group
Recruiting - verified March 2010
Cisplatin or Carboplatin Combined With Gemcitabine in Treating Patients With Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor

Condition: Head and Neck Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: gemcitabine hydrochloride
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Adjuvant Erlotinib After Completing Chemoradiotherapy in Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Condition: Head and Neck Cancer
Interventions: Drug: erlotinib hydrochloride; Procedure: adjuvant therapy
Sponsor: NCIC Clinical Trials Group
Active, not recruiting - verified March 2010
Comparison of Two Salvage Chemotherapy Regimens Before Autologous Stem Cell Transplantation With or Without Maintenance Rituximab in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Condition: Lymphoma
Interventions: Biological: rituximab; Drug: cisplatin; Drug: cytarabine; Drug: dexamethasone; Drug: gemcitabine hydrochloride; Other: clinical observation
Sponsor: NCIC Clinical Trials Group
Recruiting - verified March 2010
3-AP in Treating Patients With Previously Untreated Locally Recurrent or Metastatic Renal Cell Carcinoma

Condition: Kidney Cancer
Intervention: Drug: triapine
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI)
Completed - verified March 2010
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma

Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: cyclophosphamide; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer

Conditions: Metastatic Breast Cancer; Advanced Breast Cancer
Interventions: Drug: Letrozole; Drug: Lapatinib (GW572016)
Sponsor: GlaxoSmithKline
Active, not recruiting - verified March 2010
Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer

Condition: Carcinoma, Renal Cell
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006); Drug: Placebo
Sponsors: Bayer; Onyx Pharmaceuticals
Active, not recruiting - verified February 2010
CCI-779 in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer

Condition: Endometrial Cancer
Intervention: Drug: temsirolimus
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI)
Active, not recruiting - verified March 2010
Ecteinascidin 743 in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors

Condition: Sarcoma
Interventions: Drug: trabectedin; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Suspended - verified March 2010
Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

Condition: Breast Cancer
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Biological: trastuzumab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor

Condition: Desmoid Tumor
Interventions: Drug: sulindac; Drug: tamoxifen citrate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified July 2009
Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer

Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: exemestane
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; Southwest Oncology Group; International Breast Cancer Study Group
Active, not recruiting - verified March 2010
Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: exemestane; Drug: tamoxifen citrate
Sponsors: International Breast Cancer Study Group; National Cancer Institute (NCI); Breast International Group
Recruiting - verified March 2010
Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer

Condition: Breast Cancer
Interventions: Biological: pegfilgrastim; Drug: docetaxel; Drug: epirubicin hydrochloride
Sponsor: NCIC Clinical Trials Group
Recruiting - verified February 2009
Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer

Condition: Breast Cancer
Intervention: Drug: exemestane
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Suppression of Ovarian Function Plus Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: exemestane; Drug: tamoxifen citrate; Drug: triptorelin; Procedure: oophorectomy; Radiation: radiation therapy
Sponsors: International Breast Cancer Study Group; National Cancer Institute (NCI); Breast International Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; North Central Cancer Treatment Group; National Surgical Adjuvant Breast and Bowel Project (NSABP); Southwest Oncology Group
Recruiting - verified March 2010
The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer

Conditions: Locally Advanced Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: Fulvestrant; Drug: Exemestane
Sponsor: AstraZeneca
Active, not recruiting - verified March 2010
Vitamin E, Selenium, and Soy Protein in Preventing Cancer in Patients With High-Grade Prostate Neoplasia

Conditions: Precancerous/Nonmalignant Condition; Prostate Cancer
Interventions: Dietary Supplement: selenium; Dietary Supplement: soy protein isolate; Dietary Supplement: vitamin E
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Combination Chemotherapy With or Without Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Biological: rituximab; Drug: CHOP regimen; Drug: EPOCH regimen; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: methotrexate; Drug: mitoxantrone hydrochloride; Drug: prednisolone; Drug: prednisone; Drug: vincristine sulfate
Sponsor: NCIC Clinical Trials Group
Active, not recruiting - verified March 2010
Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Radiation: iodine I 125; Radiation: palladium Pd 103; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer

Condition: Colorectal Cancer
Interventions: Drug: capecitabine; Drug: fluorouracil; Drug: oxaliplatin; Radiation: radiation therapy
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified March 2010
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: CC-5013; Drug: Dexamethasone
Sponsor: Celgene Corporation
Completed - verified March 2010
Silymarin (Milk Thistle Extract) in Treating Patients With Acute Lymphoblastic Leukemia Who Are Receiving Chemotherapy

Conditions: Drug/Agent Toxicity by Tissue/Organ; Leukemia
Intervention: Dietary Supplement: silymarin
Sponsors: Herbert Irving Comprehensive Cancer Center; National Cancer Institute (NCI)
Active, not recruiting - verified May 2006
Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma

Conditions: Endometrial Cancer; Sarcoma
Intervention: Drug: perifosine
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI)
Completed - verified March 2010
Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors

Conditions: Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Ovarian Cancer
Interventions: Biological: bleomycin sulfate; Drug: cisplatin; Drug: etoposide; Procedure: conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Perifosine in Treating Patients With Metastatic or Recurrent Malignant Melanoma

Condition: Melanoma (Skin)
Intervention: Drug: perifosine
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI)
Completed - verified March 2010
Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: buserelin; Drug: custirsen sodium; Drug: flutamide; Procedure: conventional surgery; Procedure: neoadjuvant therapy
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Gefitinib in Treating Patients With Non-Small Cell Lung Cancer That Has Been Surgically Removed

Condition: Lung Cancer
Interventions: Drug: gefitinib; Procedure: adjuvant therapy
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Southwest Oncology Group
Active, not recruiting - verified March 2010
Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia

Condition: Leukemia
Intervention: Drug: fludarabine phosphate
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma

Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Biological: filgrastim; Biological: pegfilgrastim; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine; Drug: vincristine sulfate
Sponsors: European Organization for Research and Treatment of Cancer; Lymphoma Trials Office; Groupe d'Etudes de Lymphomes de L'Adulte; Grup per l'Estudi dels Limfomes de Catalunya i Balears; NCIC Clinical Trials Group; Australasian Leukaemia and Lymphoma Group (ALLG); Nordic Lymphoma Group
Active, not recruiting - verified June 2009
Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia

Condition: Lymphoma
Intervention: Drug: bortezomib
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group
Completed - verified March 2010
Calcium With or Without Estrogen and/or Risedronate in Preventing Osteoporosis in Patients With Prostate Cancer

Conditions: Osteoporosis; Prostate Cancer
Interventions: Dietary Supplement: calcium carbonate; Dietary Supplement: cholecalciferol; Drug: conjugated estrogens; Drug: risedronate sodium
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Completed - verified January 2007
SarCNU in Treating Patients With Recurrent Malignant Glioma

Condition: Brain and Central Nervous System Tumors
Intervention: Drug: SarCNU
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: therapeutic immune globulin; Other: clinical observation
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Who Have Undergone Stem Cell Transplantation

Condition: Lymphoma
Intervention: Radiation: radiation therapy
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Erlotinib and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Drug: carboplatin; Drug: erlotinib hydrochloride
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer

Condition: Endometrial Cancer
Intervention: Drug: erlotinib hydrochloride
Sponsor: NCIC Clinical Trials Group
Active, not recruiting - verified March 2010
Bortezomib in Treating Patients With Mantle Cell Lymphoma

Condition: Lymphoma
Intervention: Drug: bortezomib
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Comparison of Combination Chemotherapy Regimens in Treating Newly Diagnosed Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel; Drug: topotecan hydrochloride
Sponsors: NCIC Clinical Trials Group; European Organization for Research and Treatment of Cancer
Active, not recruiting - verified November 2005
SarCNU in Treating Patients With Recurrent or Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Intervention: Drug: SarCNU
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Gemcitabine With or Without Erlotinib in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Drug: erlotinib hydrochloride; Drug: gemcitabine hydrochloride
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Isotretinoin With or Without Monoclonal Antibody, Interleukin-2, and Sargramostim Following Stem Cell Transplantation in Treating Patients With Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: aldesleukin; Biological: monoclonal antibody Ch14.18; Biological: sargramostim; Drug: isotretinoin
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Condition: Prostate Cancer
Intervention: Drug: gefitinib
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer

Condition: Breast Cancer
Interventions: Drug: CMF regimen; Drug: capecitabine; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: fluorouracil; Drug: methotrexate; Procedure: adjuvant therapy
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Southwest Oncology Group; NCIC Clinical Trials Group
Completed - verified January 2007
Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma

Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: busulfan; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: melphalan; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: University Hospitals, Leicester; National Cancer Institute (NCI); Children's Cancer and Leukaemia Group; Societe Francaise Oncologie Pediatrique; European Organization for Research and Treatment of Cancer; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria; Swiss Group for Clinical Cancer Research; EBMT Solid Tumors Working Party; Children's Oncology Group
Recruiting - verified March 2010
Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia

Conditions: Anemia; Cervical Cancer; Drug/Agent Toxicity by Tissue/Organ; Radiation Toxicity
Interventions: Biological: epoetin alfa; Drug: cisplatin; Procedure: quality-of-life assessment; Radiation: brachytherapy; Radiation: radiation therapy
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI); NCIC Clinical Trials Group
Completed - verified May 2004
Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen

Condition: Cancer
Interventions: Drug: dexamethasone; Drug: ondansetron; Procedure: quality-of-life assessment
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer

Condition: Breast Cancer
Interventions: Biological: epoetin alfa; Biological: filgrastim; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: epirubicin hydrochloride; Drug: fluorouracil; Drug: paclitaxel; Procedure: adjuvant therapy
Sponsors: NCIC Clinical Trials Group; North Central Cancer Treatment Group; Southwest Oncology Group
Active, not recruiting - verified March 2010
Combination Chemotherapy in Treating Patients With Hodgkin's Disease or Non-Hodgkin's Lymphoma That Has Not Responded to Previous Treatment

Condition: Lymphoma
Interventions: Drug: cisplatin; Drug: dexamethasone; Drug: gemcitabine hydrochloride
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Intervention: Drug: lurtotecan liposome
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Screening and Diagnostic Trial to Compare the Effectiveness of Two Types of Mammography in Detecting Breast Cancer in Women

Condition: Breast Cancer
Interventions: Procedure: breast imaging study; Procedure: comparison of screening methods; Procedure: radiomammography
Sponsors: American College of Radiology Imaging Network; National Cancer Institute (NCI)
Completed - verified December 2003
Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: prednisone; Drug: thalidomide
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: temozolomide; Radiation: radiation therapy
Sponsors: European Organization for Research and Treatment of Cancer; NCIC Clinical Trials Group
Active, not recruiting - verified February 2010
Paclitaxel and Carboplatin With or Without BMS-275291 in Treating Patients With Advanced or Metastatic Non-small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel; Drug: rebimastat
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Radiation Therapy in Treating Women Who Have Undergone Surgery for Early-Stage Invasive Breast Cancer

Condition: Breast Cancer
Interventions: Procedure: adjuvant therapy; Radiation: radiation therapy
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); Radiation Therapy Oncology Group; Southwest Oncology Group; Trans-Tasman Radiation Oncology Group (TROG); North Central Cancer Treatment Group
Active, not recruiting - verified March 2010
Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors

Conditions: Head and Neck Cancer; Lung Cancer; Ovarian Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: cisplatin; Drug: lurtotecan liposome
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Flavopiridol in Treating Patients With Metastatic Malignant Melanoma

Condition: Melanoma (Skin)
Intervention: Drug: alvocidib
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Flavopiridol in Treating Patients With Recurrent, Locally Advanced, or Metastatic Soft Tissue Sarcoma

Condition: Sarcoma
Intervention: Drug: alvocidib
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Lurtotecan Liposome in Treating Patients With Advanced Solid Tumors

Condition: Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Drug: lurtotecan liposome
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
MG98 in Treating Patients With Advanced Solid Tumors

Condition: Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Drug: MG 98
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Flavopiridol in Treating Patients With Previously Untreated or Relapsed Mantle Cell Lymphoma

Condition: Lymphoma
Intervention: Drug: alvocidib
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia

Condition: Lymphoma
Intervention: Biological: rituximab
Sponsors: University of California, Los Angeles; National Cancer Institute (NCI); Genentech
Completed - verified February 2010
Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx

Conditions: Head and Neck Cancer; Oral Complications
Interventions: Procedure: management of therapy complications; Radiation: radiation therapy
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Vinorelbine Plus Cisplatin or No Further Therapy in Treating Patients With Non-small Cell Lung Cancer That Has Been Surgically Removed

Condition: Lung Cancer
Interventions: Drug: cisplatin; Drug: vinorelbine ditartrate
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI); Southwest Oncology Group; Eastern Cooperative Oncology Group; Cancer and Leukemia Group B
Completed - verified March 2010
Radiation Therapy to Relieve Symptoms in Patients With Non-small Cell Lung Cancer

Conditions: Fatigue; Lung Cancer; Nausea and Vomiting; Pain; Pulmonary Complications; Quality of Life
Interventions: Procedure: fatigue assessment and management; Procedure: nausea and vomiting therapy; Procedure: pain therapy; Procedure: quality-of-life assessment; Radiation: radiation therapy
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian Cancer

Condition: Ovarian Cancer
Intervention: Drug: ISIS 5132
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Tamoxifen in Treating Women With High-Risk Breast Cancer

Condition: Breast Cancer
Interventions: Drug: CMF regimen; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: epirubicin hydrochloride; Drug: fluorouracil; Drug: methotrexate; Drug: tamoxifen citrate; Radiation: radiation therapy
Sponsor: NCIC Clinical Trials Group
Active, not recruiting - verified March 2010
Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: buserelin; Drug: cyproterone acetate; Drug: flutamide; Drug: goserelin; Drug: leuprolide acetate; Drug: nilutamide; Procedure: orchiectomy
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI); Southwest Oncology Group
Active, not recruiting - verified March 2010
Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer

Condition: Breast Cancer
Interventions: Drug: octreotide acetate; Drug: tamoxifen citrate
Sponsor: NCIC Clinical Trials Group
Active, not recruiting - verified March 2010
Combination Chemotherapy in Treating Pain in Patients With Hormone Refractory Metastatic Prostate Cancer

Conditions: Pain; Prostate Cancer; Quality of Life
Interventions: Drug: clodronate disodium; Drug: mitoxantrone hydrochloride; Drug: prednisone; Procedure: quality-of-life assessment
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Metastatic or Recurrent Breast Cancer

Condition: Breast Cancer
Interventions: Biological: filgrastim; Drug: cisplatin; Drug: cyclophosphamide; Drug: mitoxantrone hydrochloride; Drug: tamoxifen citrate
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Monoclonal Antibody Therapy Compared With No Further Therapy After Surgery in Treating Patients With Stage II Colon Cancer

Condition: Colorectal Cancer
Intervention: Biological: edrecolomab
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Southwest Oncology Group; Eastern Cooperative Oncology Group; North Central Cancer Treatment Group; European Organization for Research and Treatment of Cancer; NCIC Clinical Trials Group
Completed - verified April 2003
Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery

Condition: Endometrial Cancer
Interventions: Procedure: adjuvant therapy; Procedure: conventional surgery; Procedure: laparoscopic surgery; Radiation: brachytherapy; Radiation: radiation therapy
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Topotecan in Treating Patients With Recurrent Brain Tumors

Condition: Brain and Central Nervous System Tumors
Intervention: Drug: topotecan hydrochloride
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast Cancer

Conditions: Breast Cancer; Neutropenia
Interventions: Biological: filgrastim; Drug: docetaxel; Drug: epirubicin hydrochloride
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Treatment for Chronic Pain in Patients With Advanced Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Pain; Precancerous/Nonmalignant Condition; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: dextromethorphan hydrobromide; Drug: morphine sulfate
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Combination Chemotherapy in Treating Patients With Multiple Myeloma

Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: dexamethasone; Drug: melphalan; Drug: prednisone
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Theophylline in Treating Cancer Patients With Shortness of Breath

Conditions: Pulmonary Complications; Quality of Life; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: theophylline; Procedure: quality-of-life assessment
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

Condition: Melanoma (Skin)
Interventions: Biological: recombinant interferon alfa; Other: clinical observation
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; Children's Oncology Group
Recruiting - verified March 2010
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy

Conditions: Anemia; Breast Cancer; Chronic Myeloproliferative Disorders; Drug/Agent Toxicity by Tissue/Organ; Leukemia; Lung Cancer; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Precancerous Condition; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: epoetin alfa; Procedure: quality-of-life assessment
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Completed - verified November 2006
Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin's Disease

Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Drug: ABVD regimen; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: vinblastine; Radiation: radiation therapy
Sponsors: NCIC Clinical Trials Group; Eastern Cooperative Oncology Group
Active, not recruiting - verified March 2010
Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix

Condition: Cervical Cancer
Interventions: Drug: cisplatin; Drug: fluorouracil; Radiation: brachytherapy; Radiation: radiation therapy
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Completed - verified February 2010
Radiation Therapy and High-Dose Corticosteroids in Treating Older Patients With Primary CNS Non-Hodgkin's Lymphoma

Condition: Lymphoma
Interventions: Drug: dexamethasone; Radiation: radiation therapy
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Completed - verified October 2003

Find Paid Clinical Trials for Cancer in Canada - Clinical Trials

Find Paid Clinical Trials for Cancer in Canada

Paid Clinical Trials and Focus Groups by Category

Main Menu

Find Clinical Trials

Clinical Trial Locations

Clinical Trial Categories

Patient Recruiting...

Paid Clinical Trials